-
2023-03-03
PharmaEngine announces Phase I clinical study of PEP07 has been approved by Australia HREC and acknowledged by Australia TGA
-
2023-01-25
PEP07: A novel, brain penetrant oral Chk1 inhibitor for the treatment of AML and MCL (6th Annual DDR Inhibitors Summit 2023)
-
2023-01-21
ONIVYDE® regimen (NALIRIFOX) demonstrated statistically significant improvement in overall survival in 1L PDAC (supplementary information)
-
2022-11-09
Positive topline results from Phase III NAPOLI-3 trial of ONIVYDE® regimen (NALIRIFOX) as a first-line treatment for previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC)
-
2022-09-25
PharmaEngine, Inc. exercised option for a worldwide exclusive license agreement to Sentinel Oncology Limited's CHK1 inhibitor
-
2022-08-04
The results from Phase III RESILIENT trial of irinotecan liposome injection (ONIVYDE®) as a second-line monotherapy treatment for small cell lung cancer (2L SCLC)
-
2022-04-18
China NMPA approves ONIVYDE® regimen for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy
-
2022-01-28
PharmaEngine, Inc. Announces First Results for ONIVYDE® in Combination with LONSURF® in Refractory Solid Tumors at 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI 2022)
-
2021-03-05
PharmaEngine and Nanobiotix to terminate Asia-Pacific Exclusive License and Collaboration Agreement for NBTXR3
-
2021-01-05
PharmaEngine, Inc. Announces First Results for PEP503(NBTXR3) in Rectal Cancer Study at ASCO-GI 2021